#China #Nanjing #TransThera #tinengotinib #biliary tract carcinoma

Promising Advances in Cancer Treatment: Tinengotinib and Atezolizumab

At the recently concluded 2024 European Society For Medical Oncology (ESMO) Asia Congress, TransThera Sciences Nanjing, Inc. shared significant clinical findings related to their novel multi-kinase inhibitor, tinengotinib. This innovative treatment was studied in conjunction with atezolizumab (Tecentriq®) to assess its effectiveness for patients with biliary tract carcinoma (BTC), a condition characterized by poor prognosis and limited treatment options after first-line therapy.

Overview of the Study

The study titled _Tinengotinib (TT-00420) in Combination with Atezolizumab in Chinese Patients with Biliary Tract Carcinoma_ presented data from a Phase Ib/II clinical trial. The trial enrolled 31 patients, all considered heavily pre-treated, underscoring the necessity for more effective treatment options for BTC—where survival rates after initial treatments remain low and unmet clinical needs are evident.

As of September 26, 2024, the results indicated promising efficacy, with objective response rates (ORR) and disease control rates (DCR) showcasing the potential of the drug combination. Specifically, among intrahepatic cholangiocarcinoma patients, an ORR of 25.0% and DCR of 80.0% were reported; while overall BTC patients recorded an ORR of 22.6% and a DCR of 74.2%. The median progression-free survival (mPFS) reached notable milestones ranging from 4.11 months to 8.77 months across different patient subsets.

Safety and Tolerability

Equally important to efficacy, the safety profile of the treatment was encouraging. Notably, no dose-limiting toxicities (DLTs) surfaced during the dose escalation phase, and the combined treatment was generally well tolerated among the patient cohort. This highlights the potential of tinengotinib to be integrated into treatment regimens for BTC without significant issues.

Implications for Future Research

The data thus far suggest a synergistic effect of tinengotinib alongside immune-checkpoint inhibitors like atezolizumab. Given the substantial unmet needs in post-first-line treatment care for BTC, these findings offer a beacon of hope for both patients and clinicians. TransThera is committed to further investigating the safety and efficacy of this combination therapy to solidify its role in future cancer treatment protocols.

About Tinengotinib

Tinengotinib represents a cutting-edge, globally examined multi-kinase inhibitor that primarily targets receptor tyrosine kinases involved in tumor growth. This investigational drug is anticipated to have a broader impact across various solid tumors beyond BTC. As a testament to its promising profile, it has already received Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the FDA and is undergoing multiple trials across the United States and China.

About TransThera

TransThera is a biopharmaceutical company dedicated to addressing significant clinical demands through innovative therapies aimed at oncology and other serious diseases. With a focus on developing first-in-class drug candidates grounded in thorough translational research and drug development strategies, TransThera is positioning itself at the forefront of medical advancements.

For additional insights and information about TransThera and their projects, please visit TransThera's website.

Final Note: This news contains forward-looking statements which involve uncertainties and risks. Actual results may vary from the projections made. Continuous monitoring and updated studies will provide a clearer understanding of the treatment's potential impact.